TC Biopharm (Holdings) Statistics
Total Valuation
TCBP has a market cap or net worth of $345,285. The enterprise value is $1.29 million.
Important Dates
The next estimated earnings date is Friday, November 29, 2024, after market close.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TCBP has 548,071 shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 548,071 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +167.33% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 1.70% |
| Float | 545,539 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.15 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 1.60.
| Current Ratio | 0.88 |
| Quick Ratio | 0.46 |
| Debt / Equity | 1.60 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -162.60 |
Financial Efficiency
Return on equity (ROE) is -1,217.48% and return on invested capital (ROIC) is -285.13%.
| Return on Equity (ROE) | -1,217.48% |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | -285.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$264,729 |
| Employee Count | 41 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.01M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.34% in the last 52 weeks. The beta is 0.25, so TCBP's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -99.34% |
| 50-Day Moving Average | 3.76 |
| 200-Day Moving Average | 8.90 |
| Relative Strength Index (RSI) | 23.09 |
| Average Volume (20 Days) | 2,328,005 |
Short Selling Information
| Short Interest | 64,929 |
| Short Previous Month | 16,525 |
| Short % of Shares Out | 11.85% |
| Short % of Float | 11.90% |
| Short Ratio (days to cover) | 0.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.05M |
| Pretax Income | n/a |
| Net Income | -10.85M |
| EBITDA | -16.32M |
| EBIT | -17.05M |
| Earnings Per Share (EPS) | -$164.45 |
Full Income StatementBalance Sheet
The company has $1.24 million in cash and $2.18 million in debt, giving a net cash position of -$943,661 or -$1.72 per share.
| Cash & Cash Equivalents | 1.24M |
| Total Debt | 2.18M |
| Net Cash | -943,661 |
| Net Cash Per Share | -$1.72 |
| Equity (Book Value) | 1.36M |
| Book Value Per Share | 4.27 |
| Working Capital | -708,298 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.68 million and capital expenditures $12,414, giving a free cash flow of -$12.70 million.
| Operating Cash Flow | -12.68M |
| Capital Expenditures | 12,414 |
| Free Cash Flow | -12.70M |
| FCF Per Share | -$23.17 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |